The ChemoStart Programme is an initiative by Insud Pharma, spearheaded by Leandro Sigman, to support innovative healthcare startups
In the second edition of the programme, 12 finalists have been shortlisted to present to a panel of experts at the Pitch Day on Thursday 31 January

Madrid, 30 January 2019.- Insud Pharma’s startup accelerator ChemoStart, spearheaded by Leandro Sigman, has one clear goal: to support innovative, disruptive healthcare solutions.

In this second edition of the programme, applications were submitted by a range of projects at different stages of development. The projects presented include a range of biotechnology solutions, ranging from new forms of pathology prevention, patient monitoring and genetic diagnosis to treatment using nanomedicines or exosomes and digital prescriptions.

“Supporting the most disruptive innovation from a range of different perspectives will allow us to tackle the healthcare challenges that lie ahead,” said Leandro Sigman, Chairman of Insud Pharma, adding: “ChemoStart seeks to underpin the entrepreneurial ecosystem in the field of health and stimulate interaction between academia, science and enterprise, allowing innovation to have a real, lasting impact on society.”

The 12 shortlisted candidates, which focus on various treatment areas such as cancer, neurological diseases and women’s health, will be presenting their projects at a Pitch Day tomorrow, 31 January, to an external panel of leading experts in various areas of healthcare.

In the next phase, two projects will be selected to receive support on areas such as internationalisation, marketing, scalability and business commercialisation.

Insud Pharma will support these startups using its own resources and the expertise of the ChemoStart mentor network, comprised of top-level specialists in a range of health-related areas.

The mentoring process will end with an Investor Day, where the candidates will pitch their projects to a group of specialist investors to secure the financing needed to support the ventures going forward.

The projects shortlisted in this edition of the initiative are:
Amadix – Liquid biopsy for early detection of cancer through blood tests before symptoms appear.
Rocío Arroyo. Website: Twitter: @AmadixDx

Aura Committed Medtech – OSCANN: an effective solution for the diagnosis of neurological disorders. 
Cecilia García Cena. Website: Twitter: @AuraInnRobotics

BioDan – Bioprinting human skin.
Contact: Alfredo Brisac. Web: Twitter: @BiodanGroup

Brainguard – Wearable system to predict migraine onset in the IoT environment.
José L. Ayala. Website: Twitter: @BrainGuardMed

B-wom – Your women’s intimate health coach.
Helena Torras. Website: Twitter: @HolaBwom

Epidisease – ScoliPro®: First diagnosis and epigenetic prognostic kit for idiopathic scoliosis.
José Luis García Giménez. Website: Twitter: @epidisease

Insulclock – Get diabetes under control with the smart insulin pen.
José Luis López Sánchez-Pascuala. Website: Twitter: @Insulclock

LeadArtis – ATTACK: Immunotherapy using T-cell recruiting antibodies.
Juan José Pérez Villar. Website: LinkedIn: LeadArtis 

Patia Diabetes – Genetics and digital tools for tailored treatment.
Jaime Razkin. Website: Twitter: @PatiaDiabetes

Pellix – Topical psoriasis treatment.
Manuel Hermida.

Reticare – Eye protection against the light emitted by LED screens.
Nilo García Manchado. Website: Twitter: @ReticareSpain

Sincrolab – Digital prescription of neurology medications.
Nacho de Ramón. Website: Twitter: @Sincrolab_es

ChemoStart is a global initiative by Insud Pharma which supports startups and companies with innovative projects in the field of health and medical care.